TRIANA Biomedicines Presents TRI-611 Orally At AACR 2026
15 Apr 2026 //
PHARMIWEB
FDA Fast-Track Designation TRIANA`s TRI-611 for ALK+ NSCLC Cancer
25 Mar 2026 //
PHARMIWEB
TRIANA Doses First Patient In TRI-611 Ph1/2 NSCLC Trial
19 Mar 2026 //
PHARMIWEB
TRIANA Biomedicines Raises 120M to Advance Glue Degrader Platform
03 Dec 2025 //
PHARMIWEB
Triana Biomedicines Appoints Caroline Germa as CMO
07 May 2025 //
ACCESSWIRE

Market Place
Sourcing Support